Possessing an airtight patent portfolio can mean the difference between success and failure in the Life Sciences industry. In-house counsel will learn from Procopio Partner Noel Gillespie how the newly issued Alice guidance to examiners by the U.S. Patent and Trademark Office (USPTO) may enable innovators to seek more patent protection of software-enabled innovations that will hold up under post-issuance scrutiny. Previous USPTO Section 101 guidance following the U.S. Supreme Court decision in Alice v. CLS Bank was considered by many to all but eliminate patentability for a wide variety of innovations, including in the medical technology and life sciences industries.
Noel will also address other timely topics, including a closely watched decision by the U.S. Supreme Court (Helsinn Healthcare v. Teva Pharmaceuticals) that could result in the loss of patentability for many inventors as a result of private sales of an invention to a third party.
This event is complimentary to attend, but please note this exclusive roundtable has limited seating and is open to in-house counsel only. Please click here to register and secure your spot.